Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 231 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ductal Carcinoma in Situ Clear all
Completed Phase 2 Interventional

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

NCT03113825
View directory record Official record
Conditions
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast, Stage II Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer
Interventions
Investigational Imaging device, AVB-620
Device · Drug
Lead sponsor
Avelas Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 9, 2026, 4:00 AM EDT
Active, not recruiting Phase 3 Interventional

Breast Cancer WEight Loss Study (BWEL Study)

NCT02750826
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Synchronous Bilateral Breast Carcinoma
Interventions
Health Education Program, Weight Loss Intervention
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
3,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1464
States / cities
Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 921 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 9, 2026, 4:00 AM EDT
Completed Phase 2 Interventional Results available

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

NCT02636582
View directory record Official record
Conditions
Breast Ductal Carcinoma In Situ
Interventions
Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure
Other · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 9, 2026, 4:00 AM EDT
Active, not recruiting Not applicable Interventional

MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ

NCT02352883
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ
Interventions
Magnetic Resonance Imaging, Therapeutic Conventional Surgery, Therapeutic Surgical Procedure, Radiation Therapy, Endocrine Therapy, Quality-of-Life Assessment, Laboratory Biomarker Analysis, Cytology Specimen Collection Procedure
Procedure · Radiation · Drug + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Female only
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
76
States / cities
San Diego, California • San Marcos, California • Greenwich, Connecticut + 56 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 9, 2026, 4:00 AM EDT
Recruiting Not applicable Interventional

A Patient Navigation Program for Addressing Disparities in Breast Cancer Care

NCT06350500
View directory record Official record
Conditions
Breast Carcinoma, Breast Ductal Carcinoma in Situ
Interventions
Patient Navigation, Questionnaire
Behavioral · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 9, 2026, 4:00 AM EDT
Not listed Not applicable Interventional

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

NCT00126464
View directory record Official record
Conditions
Breast Cancer
Interventions
fulvestrant, tamoxifen citrate, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 9, 2026, 4:00 AM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy in Treating Women With Early Stage Breast Cancer

NCT00909909
View directory record Official record
Conditions
Breast Cancer
Interventions
External beam boost, whole breast irradiation
Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
4
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey • Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 9, 2026, 4:00 AM EDT
Completed Phase 3 Interventional Results available

Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy

NCT00053898
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, tamoxifen citrate, Radiation Therapy
Drug · Radiation
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Enrollment
3,104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
724
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 499 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 9, 2026, 4:00 AM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ

NCT02908178
View directory record Official record
Conditions
Ductal Carcinoma In Situ
Interventions
Sentinel lymph node biopsy (SLNB)
Procedure
Lead sponsor
Yale University
Other
Eligibility
67 Years to 94 Years · Female only
Enrollment
28,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 9, 2026, 4:00 AM EDT
Completed Phase 2 Interventional Results available

Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

NCT01439711
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole, MRI, conventional surgery
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
32
States / cities
Los Angeles, California • Oakland, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 9, 2026, 4:00 AM EDT
Completed Not applicable Interventional

Preventing Persistent Pain and Reducing Depressive and Anxious Symptoms Following Mastectomy and Lumpectomy

NCT03430765
View directory record Official record
Conditions
Persistent Postsurgical Pain, Breast Cancer Female, Ductal Carcinoma in Situ
Interventions
Acceptance and Commitment Therapy
Behavioral
Lead sponsor
Katherine Hadlandsmyth
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 9, 2026, 4:00 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

NCT03317405
View directory record Official record
Conditions
Breast Carcinoma In Situ, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Endoxifen Hydrochloride, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 9, 2026, 4:00 AM EDT
Completed Not applicable Interventional Results available

BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)

NCT01961531
View directory record Official record
Conditions
Breast Cancer
Interventions
Accuboost APBI
Device
Lead sponsor
Brown University
Other
Eligibility
50 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
La Jolla, California • Lakeland, Florida • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 9, 2026, 4:00 AM EDT
Completed No phase listed Observational

Measuring Stress in Women With Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer or Ductal Carcinoma In Situ of the Breast

NCT00665782
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Depression, Psychosocial Effects of Cancer and Its Treatment
Interventions
laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications, psychosocial assessment and care, therapeutic conventional surgery
Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 9, 2026, 4:00 AM EDT
Completed Not applicable Interventional

Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI

NCT02587663
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Mammography, Therapeutic Conventional Surgery, Ultrasonography, Gadolinium
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 9, 2026, 4:00 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

NCT06195306
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 74 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Kansas City, Kansas • Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 9, 2026, 4:00 AM EDT
Terminated Not applicable Interventional

Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy

NCT02023008
View directory record Official record
Conditions
Anxiety Disorder, Depression, Ductal Breast Carcinoma in Situ, Fatigue, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
yoga therapy, internet-based intervention, questionnaire administration
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 9, 2026, 4:00 AM EDT
Terminated No phase listed Observational

Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women

NCT05755269
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ
Interventions
Biospecimen Collection, Genotyping, Survey Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 9, 2026, 4:00 AM EDT
Completed Not applicable Interventional

Single Fraction Intraoperative Radiotherapy

NCT01688388
View directory record Official record
Conditions
Invasive Ductal and Invasive Lobular Breast Carcinoma, Stage 0 Breast Carcinoma, Stage I Breast Carcinoma, Stage II Breast Carcinoma
Interventions
Intraoperative Radiotherapy
Procedure
Lead sponsor
St. Joseph Hospital of Orange
Other
Eligibility
41 Years to 90 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 9, 2026, 4:00 AM EDT
Completed Phase 2 Interventional

Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors

NCT02150525
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I, Breast Cancer, Stage II, Breast Cancer, Stage III
Interventions
omega-3 fatty acid, placebo, Questionnaire administration
Dietary Supplement · Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 9, 2026, 4:00 AM EDT
Completed Phase 4 Interventional

Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer

NCT00742222
View directory record Official record
Conditions
Breast Cancer, Carcinoma, Lumpectomy, Ductal Carcinoma in Situ
Interventions
Electronic Brachytherapy, Intracavitary accelerated partial breast irradiation
Radiation
Lead sponsor
Xoft, Inc.
Industry
Eligibility
50 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
8
States / cities
Tuscaloosa, Alabama • Montebello, California • Orange Park, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 9, 2026, 4:00 AM EDT
Completed Not applicable Interventional Results available

EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer

NCT05086705
View directory record Official record
Conditions
Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Hot Flashes
Interventions
EMBr Wave, Questionnaire Administration
Device · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 9, 2026, 4:00 AM EDT
Terminated Not applicable Interventional Results available

Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia

NCT03505372
View directory record Official record
Conditions
Atypical Ductal Hyperplasia
Interventions
Contrast enhanced mammography
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
30 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 9, 2026, 4:00 AM EDT
Recruiting Not applicable Interventional

Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma

NCT03909282
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ
Interventions
Lumpectomy, Partial breast irradiation prior to surgery
Procedure · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 9, 2026, 4:00 AM EDT